A detailed history of Kaye Capital Management transactions in Eli Lilly & CO stock. As of the latest transaction made, Kaye Capital Management holds 690 shares of LLY stock, worth $643,425. This represents 0.25% of its overall portfolio holdings.

Number of Shares
690
Previous 688 0.29%
Holding current value
$643,425
Previous $434 Million 99.88%
% of portfolio
0.25%
Previous 0.19%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 19, 2024

BUY
$592.2 - $792.28 $1,184 - $1,584
2 Added 0.29%
690 $536,000
Q4 2023

Jan 29, 2024

BUY
$525.19 - $619.13 $525 - $619
1 Added 0.15%
688 $434 Million
Q3 2023

Nov 06, 2023

BUY
$434.7 - $599.3 $434 - $599
1 Added 0.15%
687 $369 Million
Q2 2023

Jul 24, 2023

SELL
$350.74 - $468.98 $18,238 - $24,386
-52 Reduced 7.05%
686 $322 Million
Q1 2023

Apr 20, 2023

BUY
$310.63 - $364.82 $931 - $1,094
3 Added 0.41%
738 $253 Million
Q4 2022

Jan 18, 2023

BUY
$321.55 - $374.67 $236,339 - $275,382
735 New
735 $269 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $886B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Kaye Capital Management Portfolio

Follow Kaye Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kaye Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Kaye Capital Management with notifications on news.